Table 2.
Safety outcomes
| Nal-iri (n = 35.4) |
FOLFIRI (n = 39.3) |
|
|---|---|---|
| Reason for discontinuationa | ||
| Disease progression | 26 (75) | 21 (53) |
| Toxicity | 0 (0) | 2 (4) |
| Patient preference | 2 (7) | 11(28) |
| Physician preference | 1 (4) | 4 (10) |
| Death | 5 (13) | 2 (5) |
| ≥ 1 treatment delay | 24 (66) | 14 (36) |
| Dose reductions | ||
| Initial dose reduction | 4 (12) | 14 (34) |
| ≥ 1 dose reduction | 14 (39) | 19 (48) |
| G-CSF use | 5 (16) | 6 (15) |
| Atropine | 13 (36) | 27 (70) |
IPTW-adjusted; reported weighted counts are rounded to the nearest integer, percentages are calculated based on the unrounded weighted counts
G-CSF granulocyte-colony stimulating factor
a
One patient in the nal-iri group continued on treatment at the time of data collection